Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP419717.RAA6LCd1sz0OkcCz9OAp_no4j96-1r1TEKeWz_uK_0Lo8130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419717.RAA6LCd1sz0OkcCz9OAp_no4j96-1r1TEKeWz_uK_0Lo8130_provenance.
• NP419695.RAZJscwASvggNzQABRSIZT_8UckIbF5FuftZXNY5Zxggw130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419695.RAZJscwASvggNzQABRSIZT_8UckIbF5FuftZXNY5Zxggw130_provenance.
• NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419696.RASAdexIItoS5RnUYzlX46AlJ0lEaXkJ0NHyS0g3TGK8M130_provenance.
• NP419701.RAcifka5FdOVZdH_xZCEBH5YPZEs34oQEYzIae2DvXFUA130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419701.RAcifka5FdOVZdH_xZCEBH5YPZEs34oQEYzIae2DvXFUA130_provenance.
• NP419702.RAWVJY6JGjQnqnxxXg9SPQUrxYRMnUhkOBYE_BNqXQFv8130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419702.RAWVJY6JGjQnqnxxXg9SPQUrxYRMnUhkOBYE_BNqXQFv8130_provenance.
• NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
• NP419713.RAbdahntMor6gaUyf_sB9GaXFpiRVMH23varlVDMOxi6M130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419713.RAbdahntMor6gaUyf_sB9GaXFpiRVMH23varlVDMOxi6M130_provenance.
• NP419700.RAuWtZgGjjzJ52_SM-tE3NbwCshBfM7VFFplBQEoSu2XY130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419700.RAuWtZgGjjzJ52_SM-tE3NbwCshBfM7VFFplBQEoSu2XY130_provenance.
• NP419709.RAn7A0s51fiYyIkHP75I5ktLDeisjn6VDrcxdXj6wNDiw130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419709.RAn7A0s51fiYyIkHP75I5ktLDeisjn6VDrcxdXj6wNDiw130_provenance.
• NP419712.RAuUxMUqFgjO0l3lwnWfR96t9XXBCEimsIl8D0zVqzhtM130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419712.RAuUxMUqFgjO0l3lwnWfR96t9XXBCEimsIl8D0zVqzhtM130_provenance.
• NP419714.RAqREkxQkBqT9vltFiHFswnS9WPN4uzI4MpDWQ-IOC1yo130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419714.RAqREkxQkBqT9vltFiHFswnS9WPN4uzI4MpDWQ-IOC1yo130_provenance.
• NP419697.RAHw-tXahUZjChWOAlRgJbxIFGls9zlTzk46eqBdZURVE130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419697.RAHw-tXahUZjChWOAlRgJbxIFGls9zlTzk46eqBdZURVE130_provenance.
• NP419698.RAEzLUacSPfTmARM0Vsl7Lrh07K8qF23lf-_FmOJNhEMM130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419698.RAEzLUacSPfTmARM0Vsl7Lrh07K8qF23lf-_FmOJNhEMM130_provenance.
• NP419699.RAJx9NcDVNQfFuQZz0um-_NyPheAHMdB8U-UWc7-Jr7b8130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419699.RAJx9NcDVNQfFuQZz0um-_NyPheAHMdB8U-UWc7-Jr7b8130_provenance.
• NP419705.RAKhK-yDqevrwUU4WC71hqgMR8yXktMDwytEDylH2W9kA130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419705.RAKhK-yDqevrwUU4WC71hqgMR8yXktMDwytEDylH2W9kA130_provenance.
• NP419706.RAECgoRWeFK4KLNLkdeoS45uxYCoSEAeJ-32EgsYoe6o4130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419706.RAECgoRWeFK4KLNLkdeoS45uxYCoSEAeJ-32EgsYoe6o4130_provenance.
• NP419703.RA2Ak0mxhtCBMiTsyBgP9Z1MC1t29yATcnCI5egdyWM_M130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419703.RA2Ak0mxhtCBMiTsyBgP9Z1MC1t29yATcnCI5egdyWM_M130_provenance.
• NP419704.RA_uMNuAu0KMua-e4Z8VriMeznSGPOKrhVvhQy5VQyZTo130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419704.RA_uMNuAu0KMua-e4Z8VriMeznSGPOKrhVvhQy5VQyZTo130_provenance.
• NP419707.RA_kSu6p_ufHfoBL_qdMMEyF3yA-vrp7BIUA8Yz1LSo8I130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419707.RA_kSu6p_ufHfoBL_qdMMEyF3yA-vrp7BIUA8Yz1LSo8I130_provenance.
• NP419708.RA6GOMxgYC53KWyWBsTy8ROIW6JVVmWsyI1vyoCTCrcIc130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419708.RA6GOMxgYC53KWyWBsTy8ROIW6JVVmWsyI1vyoCTCrcIc130_provenance.
• NP419710.RAyuo8nyOsGqZX-Be_rRhKznq0KgTVwrR7raKiKckvuJk130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419710.RAyuo8nyOsGqZX-Be_rRhKznq0KgTVwrR7raKiKckvuJk130_provenance.
• NP419715.RA9XO7AP4ExbqLHTW7Y8TjxYVPc6y-PpAmK9NIvvNnIwU130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419715.RA9XO7AP4ExbqLHTW7Y8TjxYVPc6y-PpAmK9NIvvNnIwU130_provenance.
• NP419716.RA90PZQrBZ2DabWII24JI4BsT9Cn0M4n4bWgW1Em2uN8I130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419716.RA90PZQrBZ2DabWII24JI4BsT9Cn0M4n4bWgW1Em2uN8I130_provenance.